Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: SkyQuest | PRODUCT CODE: 1913151

Cover Image

PUBLISHER: SkyQuest | PRODUCT CODE: 1913151

Opioid Use Disorder Market Size, Share, and Growth Analysis, By Treatment (Methadone, Buprenorphine), By Route of Administration (Oral, Injectable / Implant), By Distribution Channel, By End-User, By Region - Industry Forecast 2026-2033

PUBLISHED:
PAGES: 175 Pages
DELIVERY TIME: 3-5 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5300
PDF & Excel (Multiple User License)
USD 6200
PDF & Excel (Enterprise License)
USD 7100

Add to Cart

Global Opioid Use Disorder Market size was valued at USD 5.7 Billion in 2024 and is poised to grow from USD 6.37 Billion in 2025 to USD 15.56 Billion by 2033, growing at a CAGR of 11.8% during the forecast period (2026-2033).

The increasing incidence of drug abuse, coupled with heightened government initiatives to enhance awareness and expand treatment facilities for opioid use disorder (OUD), is driving significant market demand. This surge is largely fueled by the rising misuse of prescription opioids, heroin, and synthetic drugs, necessitating more comprehensive treatment solutions. Global prioritization of OUD awareness and therapeutic options presents new long-term opportunities, supported by growing public and stakeholder advocacy. The proliferation of treatment centers, outpatient clinics, telehealth services, and integrated care programs has also enhanced access to care, further contributing to market growth. However, challenges such as social stigma, limited access in developing regions, high treatment costs, and regulatory barriers may hinder market expansion and penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Opioid Use Disorder market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Opioid Use Disorder Market Segments Analysis

Global Opioid Use Disorder Market is segmented by Treatment, Route of Administration, Distribution Channel, End-User and region. Based on Treatment, the market is segmented into Methadone, Buprenorphine, Naltrexone and Other Therapies. Based on Route of Administration, the market is segmented into Oral, Injectable / Implant and Transdermal / Other. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online / E-commerce. Based on End-User, the market is segmented into Outpatient Clinics, Inpatient / Residential Treatment Centres and Remote Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Opioid Use Disorder Market

The expansion of investments in research and development aimed at creating new pharmacotherapy products is significantly contributing to the treatment of various opioid use disorders. Advances such as extended-release buprenorphine injections, innovative implants, and novel antagonists like naltrexone, along with combination therapies, are opening up a multitude of opportunities for stakeholders within the market. Furthermore, these advancements not only lead to a reduction in dosing frequency but also enhance patient adherence, thus positively influencing the overall perspective of the global opioid use disorder market. This growing emphasis on innovation is shaping the landscape for effective treatment solutions.

Restraints in the Global Opioid Use Disorder Market

The Global Opioid Use Disorder market faces significant challenges due to the persistent social stigma surrounding this condition. Many individuals grappling with opioid use disorder hesitate to seek treatment due to fears of judgment, discrimination, or potential legal repercussions. This apprehension often leads to underutilization of available treatment programs and services. Furthermore, cultural barriers and feelings of shame can further inhibit individuals from accessing necessary care, ultimately stalling the growth and development of the market. Addressing these societal attitudes is crucial for improving treatment uptake and moving towards a more effective healthcare response for those affected by opioid use disorder.

Market Trends of the Global Opioid Use Disorder Market

The Global Opioid Use Disorder market is experiencing a significant shift toward long-acting and extended-release pharmacotherapies, reflecting a growing preference among clinicians and patients alike. Innovations such as buprenorphine injections and naltrexone implants are gaining traction due to their enhanced efficacy and safety profiles. These formulations not only improve adherence by reducing the frequency of dosing but also provide a more stable management of symptoms, leading to higher patient acceptance. As healthcare providers increasingly adopt these advanced treatment options, the demand for long-acting therapies is poised to reshape the market landscape, highlighting a promising trend in combating opioid use disorders effectively.

Product Code: SQMIG35D2365

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Technology Assessment
  • Regulatory Landscape

Global Opioid Use Disorder Market Size by Treatment & CAGR (2026-2033)

  • Market Overview
  • Methadone
  • Buprenorphine
  • Naltrexone
  • Other Therapies

Global Opioid Use Disorder Market Size by Route of Administration & CAGR (2026-2033)

  • Market Overview
  • Oral
  • Injectable / Implant
  • Transdermal / Other

Global Opioid Use Disorder Market Size by Distribution Channel & CAGR (2026-2033)

  • Market Overview
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online / E-commerce

Global Opioid Use Disorder Market Size by End-User & CAGR (2026-2033)

  • Market Overview
  • Outpatient Clinics
  • Inpatient / Residential Treatment Centres
  • Remote Care

Global Opioid Use Disorder Market Size & CAGR (2026-2033)

  • North America (Treatment, Route of Administration, Distribution Channel, End-User)
    • US
    • Canada
  • Europe (Treatment, Route of Administration, Distribution Channel, End-User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Treatment, Route of Administration, Distribution Channel, End-User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Treatment, Route of Administration, Distribution Channel, End-User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Treatment, Route of Administration, Distribution Channel, End-User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Indivior PLC
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Alkermes plc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Orexo AB
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Camurus AB
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hikma Pharmaceuticals PLC
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Titan Pharmaceuticals Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Omeros Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson Services, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim GmbH
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Purdue Pharma L.P.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ZLB Behring
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mallinckrodt Pharmaceuticals
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sandoz
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ViiV Healthcare
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Camurus AB
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!